Novartis cuts uneasy 20-year ties to Roche with $20.7 billion voting stake sale

Novartis AG said on Thursday it would sell its nearly one-third voting stake in Roche back to its cross-town rival for $20.7 billion, disentangling the two competitors that had been linked by the investment for more than two decades.

Related Keywords

Zurich ,Züsz ,Switzerland ,Swiss ,Ludwig Burger ,Silke Koltrowitz ,Riham Alkousaa ,Michael Shields ,Paul Arnoldediting ,Kim Coghill ,Barbara Lewis ,Martin Ebner ,Thomson Reuters Trust Principles ,Novartis ,Chief Executive Vas Narasimhan ,Thomson Reuters Trust ,Roche ,Company News ,Deals ,Dividends ,Divestitures Spin Offs ,Europe ,Financials Legacy ,Equity Capital Changes ,Content Produced In Gdynia ,Mergers Acquisitions Takeovers ,Pictures ,Major News ,Pharmaceuticals Nec Trbc Level 5 ,Performance Results Earnings ,Results Forecasts Warnings ,Reuters Top News ,Western Europe ,